Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the First Quarter, Second Quarter, Third Quarter and Fourth Quarter of 2024
March 01, 2024 at 08:30 am EST
Share
Rapid Micro Biosystems, Inc. provided revenue guidance for the first quarter, second quarter, third quarter and fourth quarter of 2024. The company expects total revenue of at least $5.5 million in first quarter, which assumes at least 3 system placements.
The company expects revenue and placements in second quarter and third quarter to be higher than first quarter, and then peak in fourth quarter.
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission critical automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control, testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
RAPID MICRO BIOSYSTEMS, INC. 
